Shuminer, CEO of Piere, says daily purchases, like coffees, aren't the problem. Piere aims to automate financial optimization by finding the best deals. Young professionals are leaving thousands ...

Hundreds of militants from radical Togolese opposition parties—including the National Alliance for Change (ANC), led by Jean-Pierre Fabre, and the Democratic Forces for the Republic (FDR), both ...

CHARLESTON, S.C. (WCIV) — Most Rev. Jacques Fabre-Jeune, CS, will lead a special Mass at the Cathedral of St. John the Baptist on Wednesday. The Mass is intended to offer prayers for the College ...

OTTAWA — On Sunday, Conservative Leader Pierre Poilievre unveiled a bold plan: he wanted to save 50,000 lives that could be lost to Canada’s toxic drug and overdose crisis, and he was ready to ...

RedRidge will hold exclusive commercial rights in the United States, Canada, and Japan for both programs, while Pierre Fabre Laboratories will hold exclusive rest-of-world rights. In addition ...

CASTRES, France, CAMBRIDGE, Massachusetts and BASEL, Switzerland, March 12, 2025 /CNW/ -- Pierre Fabre Laboratories and RedRidge Bio ("RedRidge") today announced an exclusive R&D collaboration and ...

Pierre Fabre SA and Redridge Bio AG have signed an exclusive R&D collaboration and license agreement to identify and develop biparatopic antibody drug candidates against multiple targets, with a focus ...

Then in 2023, Pierre Fabre took on the drug's U.S. rights in a deal worth up to $640 million. Related In deal worth up to $640M, Pierre Fabre doubles down on its T-cell partnership with Atara ...

French director Jean-Pierre Jeunet has announced he is adapting bestselling novel Changer l’eau des fleurs by Valérie Perrin, with Leïla Bekhti in the lead role as a beloved cemetery caretaker ...

Kirby Bernard Fabre Sr., 92, a native of Montegut, Louisiana, and resident of Bourg, Louisiana, passed away on October 26, 2024 at Terrebonne General Hospital. Kirby was a blessing to many ...

Pierre Fabre Laboratories Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-002/VERT-002, an Innovative Targeted Therapy Intended to Treat Non-Small Cell Lung Cancer with MET ...